SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dupuis LL, Milne-Wren C, Cassidy M, et al. Symptom assessment in children receiving cancer therapy: The parents' perspective. Support Care Cancer 2010;18:281299.
  • 2
    Hinds PS, Gattuso JS, Billups CA, et al. Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 2009;45:20072014.
  • 3
    O'Kane A. An evaluation of the implementation of the MASCC anti-emetic guideline for anthracycline-cyclophosphamide based chemotherapy in female patients [abstract]. Support Care Cancer 2010;18:S82S83.
  • 4
    Dupuis L, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2011;57:191198.
  • 5
    Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients, 2010. (Accessed November 11, 2012, at http://www.pogo.ca/healthcare/practiceguidelines/).
  • 6
    Guideline for the Prevention of Acute Nausea, Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients, 2012. (Accessed November 11, 2012, at http://www.pogo.ca/healthcare/practiceguidelines/).
  • 7
    The ADAPTE Collaboration. (Accessed January 20, 2009, at http://www.adapte.org/ .).
  • 8
    CAN-IMPLEMENT©: A Guideline Adaptation and Implementation Planning Resource, 2011. Queen's University School of Nursing and Canadian Partnership Against Cancer, 2011. (Accessed June 30, 2011, at http://www.cancerview.ca/idc/groups/public/documents/webcontent/can_implement_guide_lines.pdf).
  • 9
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177188.
  • 10
    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924926.
  • 11
    Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guidelines for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24:29322947.
  • 12
    Basch E, Prestrud A, Hesketh P, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011;29:41894198.
  • 13
    Tipton J, McDaniel R, Barbour L, et al. Putting evidence into practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2007;11:6978.
  • 14
    Alvarez O, Freeman A. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145150.
  • 15
    Ozkan A, Yildiz I, Yuksel L, et al. Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Jpn J Clin Oncol 1999;29:9295.
  • 16
    Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006;106:931940.
  • 17
    Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multi-national, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:41124119. Pregent, E. Merck Frosst Canada Ltd, Personal communication to L. L. Dupuis March 14, 2007.
  • 18
    Phillips R, Gopaul S, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2010; 187. Art. No.: CD007786. DOI: 10.1002/14651858.CD007786.pub2
  • 19
    White L, Daly S, McKenna C, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 2000;17:445455.
  • 20
    Nadaraja S, Mamoudou A, Thomassen H, et al. Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 2012;59:870873.
  • 21
    Koseoglu V, Kurekci A, Atay A, et al. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated withantineoplastic chemotherapy: A prospective randomized study. Eur J Pediatr 1998;157:806810.
  • 22
    Sandoval C, Corbi D, Strobino B, et al. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 1999;17:309313.
  • 23
    Hirota T, Honjo T, Kuroda R, et al. Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis. Jpn J Cancer Chemother 1993;20:23692373.
  • 24
    Gore L, Chawla SP, Petrilli AS, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52:242247.
  • 25
    Choi M, Jiles C, Seibel N. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting. J Pediatr Hematol Oncol 2010;32:e268e271.
  • 26
    Marshall G, Kerr S, Vowels M, et al. Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine. J Pediatr 1989;115:156160.
  • 27
    Mehta P, Gross S, Graham-Pole J, et al. Methylprednisolone for chemotherapy-induced emesis: A double-blind randomized trial in children. J Pediatr 1986;108:774776.
  • 28
    Tramer M, Carrroll F, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: Quantitative systematic review. BMJ 2001;323:18.
  • 29
    Chan H, Correia J, MacLeod S. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 1987;79:946952.
  • 30
    Ouellet G, Therrien R. Utilisation de l'aprepitant pour les nauseea et les vomissements regractaries secondaires a la chimiotherapie chez une adolescente. Pharmactuel 2005;38:220225.
  • 31
    Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005;45:857860.
  • 32
    Vianello O, Manfredini L, Miano M, et al. Effect of aprepitant on antiemetic protection in adolescents with cancer receiving highly emetogenic chemotherapy: A preliminary experience [abstract]. Support Care Cancer 2005;13:422.
  • 33
    Coppola D, Rodriguez V, Graner K, et al. Use of aprepitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients [abstract]. J Pediatr Pharmacol Ther 2008;13:191.
  • 34
    Hahlen K, Quintana E. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995;126:309313.
  • 35
    Relling MV, Mulhern RK, Fairclough D, et al. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr 1993;123:811816.
  • 36
    Zeltzer L, LeBaron S, Zeltzer P. Paradoxical effects of prophylactic phenothiazine antiemetics in children receiving chemotherapy. J Clin Oncol 1984;2:930936.
  • 37
    Graham-Pole J, Weare J, Engel S, et al. Antiemetics in children receiving cancer chemotherapy: A double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol 1986;4:11101113.
  • 38
    Sumer T, Abu-Melha A, Maqbool G, et al. Dexamethasone as an antiemetic in children receiving cis-platinum. Am J Pediatr Hematol Oncol 1988;10:126128.
  • 39
    Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995;73:243245.
  • 40
    Yang L, Panetta J, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:19321939.
  • 41
    Komada Y, Matsuyama T, Takao A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukemia receiving emetogenic chemotherapy. Eur J Cancer 1999;35:10951101.
  • 42
    Fujimoto T, Hirota T, Shimizu H, et al. A controlled, dose-comparison study of granisetron for nausea and vomiting induced by cancer chemotherapy in children. Int J Clin Oncol 1996;1:5760.
  • 43
    Tsuchida Y, Hayashi Y, Asami K, et al. Effects of granisetron in children undergoing high-dose chemotherapy: A multi-institutional, cross-over study. Int J Clin Oncol 1999;14:673679.
  • 44
    Jacobson S, Shore R, Greenberg ML, et al. The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol Oncol 1994;16:231235.
  • 45
    Mabro M, Cohn R, Zanesco L, et al. Granisetron en solution buvable dans la prevention des vomissements chimio-induits de l'enfant: Comparison en double aveugle de deux posologies. Bull Cancer 2000;87:259264.
  • 46
    Aksoylar S, Akman SA, Ozgenc F, et al. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 2001;18:397406.
  • 47
    Basade M, Kulkarni SS, Dhar AK, et al. Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy. Indian Pediatr 1996;33:321323.
  • 48
    Dalzell A, Bartlett H, Lilleyman J. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986;61:502505.
  • 49
    Brock P, Brichard B, Rechnitzer C, et al. An increased loading dose of ondansetron: A North European, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2. Eur J Cancer 1996; 32A: 17441748.
  • 50
    Cohen I, Zehavi N, Buchwald I, et al. Oral ondansetron: An effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol 1995;12:6772.
  • 51
    Hewitt M, Cornish J, Pamphilon D, et al. Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist. Bone Marrow Transplant 1991;7:431433.
  • 52
    Holdsworth MT, Raisch DW, Duncan MH, et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 1995;29:1621.
  • 53
    Holdsworth MT, Adam VR. Computerized system for outcomes-based antiemetic therapy in children. Ann Pharmacother 2000;34:11011108.
  • 54
    Pinkerton CR, Williams D, Wootton C, et al. 5-HT3 antagonist ondansetron—An effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990;65:822825.
  • 55
    Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol 1993;5:1114.
  • 56
    Corapcioglu F, Sarper N. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. Pediatr Hematol Oncol 2005;22:103114.
  • 57
    Jaing T-H, Tsay P-K, Hung I-J, et al. Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with actue lymphoblastic leukemia. Pediatr Hematol Oncol 2004;21:227235.
  • 58
    Parker RI, Prakash D, Mahan RA, et al. Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. J Pediatr Hematol Oncol 2001;23:578581.
  • 59
    Holdsworth MT, Raisch DW, Winter SS, et al. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer 1998;6:132138.
  • 60
    Drug FDA Communication: Safety New information regarding QT prolongation with ondansetron (Zofran), June 29, 2012. (Accessed August 27, 2012, at http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm).